新股消息 | 普祺医药递表港交所 核心产品普美昔替尼凝胶已完成III期临床试验

Company Overview - Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharmaceutical) focuses on immunoinflammatory diseases and aims to be a leader in localized targeted therapies [4] - The company was established in 2016 and emphasizes innovative design and precise localized delivery in treating chronic inflammatory diseases [4] - Puqi Pharmaceutical has developed a pipeline of innovative products based on its understanding of immune signaling pathways, particularly the JAK-STAT pathway [4] Product Pipeline - Core product PG-011 (Pumeixinine) includes two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis, both of which are in advanced clinical trials [5] - PG-033 is a tablet for pruritus, currently in Phase I trials, targeting conditions with unmet medical needs [6] - PG-018 is a dual-target JAK1-ROCK inhibitor for autoimmune kidney diseases, also in Phase I trials [6] - PG-040 is a dual-target eye drop for glaucoma, aiming to provide better neuroprotection compared to traditional therapies [7] Financial Performance - For the fiscal year 2024, the company reported net income of 11.22 million RMB, with losses of approximately 178.5 million RMB [8] - The financial data for the nine months ending September 30, 2024, shows net income of 819,000 RMB and losses of 132.6 million RMB [8] Industry Overview - The global autoimmune disease drug market is projected to grow from $116.9 billion in 2019 to $143.1 billion in 2024, with a CAGR of 4.1% [9] - The Chinese autoimmune disease drug market is expected to increase from 16.2 billion RMB in 2019 to 32.8 billion RMB in 2024, with a CAGR of 15.1% [12] - The global allergy disease drug market is anticipated to rise from $45.5 billion in 2019 to $68.8 billion in 2024, with a CAGR of 8.6% [14] - The Chinese allergy disease drug market is projected to grow from 30.5 billion RMB in 2019 to 57.5 billion RMB in 2024, with a CAGR of 13.5% [16] Market Potential for Atopic Dermatitis - The number of atopic dermatitis patients in China is expected to reach 72.9 million by 2024, with a CAGR of 2.1% from 2019 to 2024 [18] - The market for atopic dermatitis drugs in China is projected to grow to 11 billion RMB in 2024, with a CAGR of 28.1% from 2024 to 2028 [20]